Intercept Pharm (ICPT) Posts Q2 Loss of 79c/Share; Issues Positive FLINT Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Intercept Pharmaceuticals (ICPT) Bullish Stance Reiterated at BMO Capital Following FLINT Data
August 12, 2014 9:07 AM EDTBMO Capital analyst Jim Birchenough, M.D. reiterated an Outperform rating and $515 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following receipt of a draft manuscript for the FLINT OCA NASH trial authored by NIDDK.
Birchenough said, "We believe the results are better than expected with... More
Intercept Pharmaceuticals (ICPT) PT Lifted to $456 at Nomura Amid Positive Top-Line FLINT Data
August 12, 2014 9:03 AM EDTNomura Securities analyst M. Ian Somaiya reiterated a Buy rating on Intercept Pharmaceuticals (NASDAQ: ICPT) and boosted his price target to $456.00 (from $323.00) ) following positive top-line FLINT data.
Somaiya commented, "The results greatly de-risk the regulatory process for OCA in NASH and could... More
Leerink Swann Upgrades Intercept Pharmaceuticals (ICPT) to Outperform
August 12, 2014 8:18 AM EDTLeerink Swann upgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Market Perform to Outperform with a price target of $445.00 (from $270.00).
For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.
Shares of Intercept Pharmaceuticals closed at $237.18 yesterday.
... MoreIntercept Pharma (ICPT) trading halted with news pending
August 11, 2014 4:00 PM EDTIntercept Pharma (NASDAQ: ICPT) trading halted with news pending.
... More